针对难治性急性髓系白血病的新型信号通路
Targeting novel signaling pathways for resistant acute myeloid leukemia.
作者信息
Sakamoto Kathleen M, Grant Steven, Saleiro Diana, Crispino John D, Hijiya Nobuko, Giles Francis, Platanias Leonidas, Eklund Elizabeth A
机构信息
Division of Hematology/Oncology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Division of Hematology/Oncology and Palliative Care, Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.
出版信息
Mol Genet Metab. 2015 Mar;114(3):397-402. doi: 10.1016/j.ymgme.2014.11.017. Epub 2014 Dec 5.
Abstract
Acute myeloid leukemia (AML) is a hematologic malignancy that is the most common type of acute leukemia diagnosed in adults and the second most common type in children. The overall survival is poor and treatment is associated with significant complications and even death. In addition, a significant number of patients will not respond to therapy or relapse. In this review, several new signaling proteins aberrantly regulated in AML are described, including CREB, Triad1, Bcl-2 family members, Stat3, and mTOR/MEK. Identifying more effective and less toxic agents will provide novel approaches to treat AML.
摘要
急性髓系白血病（AML）是一种血液系统恶性肿瘤，是成人中最常见的急性白血病类型，在儿童中是第二常见类型。总体生存率较低，治疗会伴有严重并发症甚至死亡。此外，相当数量的患者对治疗无反应或会复发。在本综述中，描述了几种在AML中异常调节的新信号蛋白，包括CREB、Triad1、Bcl-2家族成员、Stat3和mTOR/MEK。识别更有效且毒性更小的药物将为治疗AML提供新方法。
相似文献
1
Targeting novel signaling pathways for resistant acute myeloid leukemia.针对难治性急性髓系白血病的新型信号通路
Mol Genet Metab. 2015 Mar;114(3):397-402. doi: 10.1016/j.ymgme.2014.11.017. Epub 2014 Dec 5.
2
Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?针对人类急性髓系白血病细胞代谢——不仅仅是针对异柠檬酸脱氢酶突变和PI3K/AKT/mTOR信号通路？
Eur J Haematol. 2016 Mar;96(3):211-21. doi: 10.1111/ejh.12690. Epub 2015 Nov 26.
3
STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia.信号转导和转录激活因子3（STAT3）作为人类恶性肿瘤的潜在治疗靶点：来自急性髓系白血病的经验教训
Expert Rev Hematol. 2015 Feb;8(1):29-41. doi: 10.1586/17474086.2015.971005. Epub 2014 Nov 6.
4
Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.同时靶向Bcl-2和mTOR信号通路可在对BH3模拟物耐药的急性淋巴细胞白血病中引发协同凋亡。
Oncotarget. 2015 Oct 13;6(31):32089-103. doi: 10.18632/oncotarget.5156.
5
Novel drug therapies in myeloid leukemia.髓系白血病的新型药物疗法
Pharm Pat Anal. 2015;4(3):187-205. doi: 10.4155/ppa.15.3.
6
Deregulation of signaling pathways in acute myeloid leukemia.急性髓系白血病中信号通路的失调
Semin Oncol. 2008 Aug;35(4):336-45. doi: 10.1053/j.seminoncol.2008.04.004.
7
The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.Bcl-2/Bax 和 Ras/Raf/MEK/ERK 信号通路：在小儿白血病发病机制中的意义及治疗方法的新展望。
Expert Rev Hematol. 2013 Oct;6(5):587-97. doi: 10.1586/17474086.2013.827415. Epub 2013 Oct 2.
8
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.单细胞质谱流式细胞术揭示了FLT3-ITD突变的急性髓系白血病干/祖细胞中的细胞内存活/增殖信号。
Cytometry A. 2015 Apr;87(4):346-56. doi: 10.1002/cyto.a.22628. Epub 2015 Jan 16.
9
New targets in pediatric Acute Myeloid Leukemia.儿科急性髓细胞白血病的新靶点。
Immunol Lett. 2013 Sep-Oct;155(1-2):47-50. doi: 10.1016/j.imlet.2013.09.012. Epub 2013 Oct 8.
10
The short form of RON is expressed in acute myeloid leukemia and sensitizes leukemic cells to cMET inhibitors.RON 的短形式在急性髓性白血病中表达，并使白血病细胞对 cMET 抑制剂敏感。
Leukemia. 2013 Feb;27(2):325-35. doi: 10.1038/leu.2012.240. Epub 2012 Aug 20.
引用本文的文献
1
CD36 as a marker of acute myeloid leukemia prognosis: A systematic review.CD36作为急性髓系白血病预后标志物的系统评价
Hematol Transfus Cell Ther. 2025 Jun 16;47(3):103861. doi: 10.1016/j.htct.2025.103861.
2
Selinexor in acute myeloid leukemia: therapeutic applications and current challenges.塞利尼索在急性髓系白血病中的应用：治疗作用与当前挑战
Front Pharmacol. 2025 May 20;16:1602911. doi: 10.3389/fphar.2025.1602911. eCollection 2025.
3
RSK1 and RSK2 as therapeutic targets: an up-to-date snapshot of emerging data.核糖體S6激酶1和核糖體S6激酶2作為治療靶點：新興數據的最新概述
Expert Opin Ther Targets. 2024 Dec;28(12):1047-1059. doi: 10.1080/14728222.2024.2433123. Epub 2024 Dec 4.
4
The nuclear GYF protein CD2BP2/U5-52K is required for T cell homeostasis.核 GYF 蛋白 CD2BP2/U5-52K 是 T 细胞稳态所必需的。
Front Immunol. 2024 Sep 6;15:1415839. doi: 10.3389/fimmu.2024.1415839. eCollection 2024.
5
Inhibition of JAK/STAT3 Expression by Acute Myeloid Leukemia-Targeted Nanoliposome for Chemotherapy Enhancement.急性髓系白血病靶向纳米脂质体对JAK/STAT3表达的抑制作用以增强化疗效果
ACS Omega. 2024 Aug 28;9(36):37901-37909. doi: 10.1021/acsomega.4c00710. eCollection 2024 Sep 10.
6
Bi-functional CpG-STAT3 decoy oligonucleotide triggers multilineage differentiation of acute myeloid leukemia in mice.双功能CpG-STAT3诱饵寡核苷酸触发小鼠急性髓系白血病多谱系分化。
Mol Ther Nucleic Acids. 2024 Jul 16;35(3):102268. doi: 10.1016/j.omtn.2024.102268. eCollection 2024 Sep 10.
7
Notch activator cyclopiazonic acid induces apoptosis in HL-60 cells through calcineurin activation.Notch 激活剂环匹阿尼酸通过钙调神经磷酸酶的激活诱导 HL-60 细胞凋亡。
J Antibiot (Tokyo). 2024 Jan;77(1):30-38. doi: 10.1038/s41429-023-00673-4. Epub 2023 Nov 8.
8
The roles of ubiquitination in AML.泛素化在 AML 中的作用。
Ann Hematol. 2024 Sep;103(9):3413-3428. doi: 10.1007/s00277-023-05415-y. Epub 2023 Aug 21.
9
The m6A modulator-mediated cytarabine sensitivity and immune cell infiltration signature in acute myeloid leukemia.m6A 调节剂介导的阿糖胞苷敏感性和急性髓系白血病中的免疫细胞浸润特征。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11457-11469. doi: 10.1007/s00432-023-05029-x. Epub 2023 Jun 30.
10
Analysis of prognostic biomarker models and immune microenvironment in acute myeloid leukemia by integrative bioinformatics.基于综合生物信息学的急性髓系白血病预后生物标志物模型与免疫微环境分析。
J Cancer Res Clin Oncol. 2023 Sep;149(12):9609-9619. doi: 10.1007/s00432-023-04871-3. Epub 2023 May 24.
本文引用的文献
1
New strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.急性髓系白血病的新策略：白血病发生与个性化医疗
Clin Cancer Res. 2014 Dec 15;20(24):6233-41. doi: 10.1158/1078-0432.CCR-14-0900. Epub 2014 Oct 16.
2
Acute myeloid leukemia: 2014 update on risk-stratification and management.急性髓系白血病：2014 年风险分层与管理更新。
Am J Hematol. 2014 Nov;89(11):1063-81. doi: 10.1002/ajh.23834.
3
New insights in AML biology from genomic analysis.从基因组分析看 AML 生物学的新见解。
Semin Hematol. 2014 Oct;51(4):282-97. doi: 10.1053/j.seminhematol.2014.08.005. Epub 2014 Aug 4.
4
γCaMKII shuttles Ca²⁺/CaM to the nucleus to trigger CREB phosphorylation and gene expression.γ钙调蛋白激酶II将钙离子/钙调蛋白转运至细胞核，以触发环磷腺苷效应元件结合蛋白的磷酸化及基因表达。
Cell. 2014 Oct 9;159(2):281-94. doi: 10.1016/j.cell.2014.09.019.
5
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.癌基因成瘾性肿瘤细胞中反馈激活 Stat3 导致的耐药性。
Cancer Cell. 2014 Aug 11;26(2):207-21. doi: 10.1016/j.ccr.2014.05.019. Epub 2014 Jul 24.
6
Co-inhibition of NF-κB and JNK is synergistic in TNF-expressing human AML.在表达 TNF 的人 AML 中，NF-κB 和 JNK 的共抑制具有协同作用。
J Exp Med. 2014 Jun 2;211(6):1093-108. doi: 10.1084/jem.20130990. Epub 2014 May 19.
7
Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells.通过同时抑制MEK、mTOR和Bcl-2诱导人急性髓性白血病细胞凋亡的评估
Mol Cancer Ther. 2014 Jul;13(7):1848-59. doi: 10.1158/1535-7163.MCT-13-0576. Epub 2014 Apr 16.
8
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission.人类急性髓系白血病中的白血病前期突变影响表观遗传调节剂，并在缓解期持续存在。
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2548-53. doi: 10.1073/pnas.1324297111. Epub 2014 Feb 3.
9
Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.携带MLL融合基因或具有急性早幼粒细胞白血病表型的急性髓系白血病细胞对Bcl-2选择性抑制剂ABT-199敏感。
Leukemia. 2014 Jul;28(7):1557-60. doi: 10.1038/leu.2014.72. Epub 2014 Feb 17.
10
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia.急性白血病中白血病前造血干细胞的鉴定。
Nature. 2014 Feb 20;506(7488):328-33. doi: 10.1038/nature13038. Epub 2014 Feb 12.
Zotero 插件